Business Context and Reporting Period
Sunshine Biopharma Inc., a small business issuer incorporated in Colorado with principal offices in Montreal, Canada, filed this Form 8-K on November 12, 2009. The report details an unregistered sale of equity securities pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Key Financial Metrics
This filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to a capital transaction:
- Convertible Notes Converted: $30,000 aggregate principal amount.
- Shares Issued: 6,750,000 shares of Common Stock.
- Recipients: Seven persons/entities (one U.S. resident).
Material Changes
Effective November 12, 2009, the company executed a conversion of debt to equity. Holders of convertible promissory notes elected to convert $30,000 of principal into 6,750,000 shares of Common Stock. This transaction resulted in an increase in the company's outstanding share count and a corresponding reduction in its convertible debt obligations.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. The issuance of shares relied upon exemptions from registration under Section 4(2), Regulation D, and Regulation S of the Securities Act of 1933.
Investor Verification Checklist
- Verify the updated total number of outstanding shares of Common Stock following the issuance of 6,750,000 shares.
- Confirm the remaining principal balance of any outstanding convertible promissory notes.
- Review the company's most recent 10-K or 10-Q for baseline financial health, as this 8-K does not contain operational or liquidity data.
- Check for any subsequent filings regarding the status of the seven recipients, particularly the U.S. resident, to ensure compliance with applicable securities laws.